We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Virological Response to Initial Antiretroviral Regimens Containing Abacavir or Tenofovir.
- Authors
Bansi, Loveleen; Sabin, Caroline; Gilson, Richard; Gazzard, Brian; Leen, Clifford; Anderson, Jane; Dunn, David; Hill, Teresa; Fisher, Martin; Ainsworth, Jonathan; Pillay, Deenan; Johnson, Margaret; Walsh, John; Orkin, Chloe; Easterbrook, Philippa; Gompels, Mark; Phillips, Andrew
- Abstract
Patients with a baseline viral load 1100,000 copies/mL receiving abacavir (ABC) as part of the nucleoside-backbone component of their first highly active antiretroviral therapy (HAART) regimen have been reported to have a greater failure rate than those receiving tenofovir (TDF). We analyzed short-term outcomes of the use of HAART combinations that included ABC or TDF. The mean 2-8-week change in viral load was calculated using linear regression. In total, 1136 patients started ABC, and 412 started TDF. After adjustment for baseline viral load and other factors, there was no difference in the change in viral load between the patients who started ABC and those who started TDF (0.03 [95% confidence interval, -0.07 to 0.12]) log copies/mL; P=.59). Furthermore, there was no evidence that this effect differed according to baseline viral load (P=.88 for the interaction between pre-HAART viral load and nucleoside started). Likewise, there was no difference in rates of virological failure between the 2 drugs at 24-48 weeks after starting HAART.
- Subjects
NEUROVIROLOGY; ACYCLOVIR; RIBAVIRIN; IMMUNE system; HIV; SPINE; ANTIVIRAL agents
- Publication
Journal of Infectious Diseases, 2009, Vol 200, Issue 5, p710
- ISSN
0022-1899
- Publication type
Article
- DOI
10.1086/605024